

Coronavirus Disease 2019 (COVID19)

Situation Report – 290

4.1.2021 at 11:00 AM



SAARC Disaster Management Centre (IU)

COVID-19 cases in the SAARC Member States

Country	Total Cases	Total Deaths	Recovered
Afghanistan	52,836	2230	42,236
Bangladesh	5,16,019	7626	4,60,598
Bhutan	716	0	450
India	1,03,40,469	1,49,649	99,46,867
Maldives	13,867	48	13,190
Nepal	2,61,859	1878	2,54,494
Pakistan	4,83,908	10258	3,84,719
Sri Lanka	44774	213	37252
Total	1,17,14,448	1,71,902	1,11,39,806

Source (in order of countries):

WHO Eastern Mediterranean Regional Office (as reported on 3.1.2021 at 16:30),

Institute of epidemiology, Disease Control and Research, Govt. of Bangladesh (as on 3.1.2021)

Ministry of Health, Royal Govt. of Bhutan (as on 4.1.2021)

Ministry of Health & Family Welfare, Govt. of India (as on 4.1.2021 at 08:00 AM)

Ministry of Health, Republic of Maldives (as on 3 January 2021 – 21:33 PM)

Ministry of Health and Population, Govt. of Nepal (as on 3 January 2021)

covid19.who.int/region/emro/country/pk (3 January 2021)



Epidemiology Unit, Ministry of Health, Govt. of Sri Lanka (as on 08:30 PM, 3.1.2021)

As of 3rd January 2021-83,322,449 people have been affected by COVID-19 worldwide. About 1,831,412 lives have been lost. (Source: WHO)

- SAARC region comprises of over 21% of the world's population which remains vulnerable towards COVID-19. The Member States have reported 1,17,14,448 cases, a total of 1,71,902 deaths in the region, and 1,11,39,806 recovered cases.

- Based on the day wise data of COVID-19 cases in the SAARC Member States, time-series graphs below show the trend of daily cases and cumulative figures (*in log scale*):

Regional Situation





SAARC Disaster Management Centre (IU)

- India: Central Drugs Standard Control Organisation has decided to accept the recommendations of the Subject Expert Committee and accordingly, vaccines of Serum Institute of India and Bharat Biotech are being approved for restricted use in emergency situation and permission is being granted to Cadila Healthcare ltd. for conduct of the Phase III clinical trial. *(Source: pib.gov.in)*